Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell Corporation (Nasdaq: ICCC) is an animal health company that develops, manufactures and markets scientifically proven and practical products to improve the health and productivity of dairy and beef cattle. News about ImmuCell often centers on sales performance for its First Defense® product line, strategic decisions regarding its Re-Tain® mastitis treatment candidate, and updates on manufacturing capacity and financing.
Investors following ICCC news can expect regular preliminary, unaudited product sales updates shortly after quarter-end, followed by detailed unaudited financial results releases. These announcements typically include commentary on product sales trends for First Defense®, including Tri-Shield® and Dual-Force® variants, domestic and international sales mix, gross margin performance, and the impact of prior production backlogs and inventory rebuilding.
Company news also covers strategic shifts, such as ImmuCell’s decision to focus resources on expanding the First Defense® franchise after receiving an FDA Incomplete Letter for the Re-Tain® New Animal Drug Application. Releases describe plans to increase the First Defense® sales force, expand manufacturing capacity, repurpose assets, and complete investigational Re-Tain® studies to support potential licensing or partnership opportunities.
Additional ICCC news items include leadership changes, such as the selection and onboarding of a new President and CEO, bank debt refinancing transactions, extensions of credit facilities, and details of conference calls with investors. For readers tracking ICCC, this news feed provides a centralized view of operational updates, product development milestones, capital structure developments and management commentary related to ImmuCell’s cattle health business.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited Q1 2026 product sales of $10.4 million, a 28.4% increase versus Q1 2025. Domestic sales rose 35.7% to $9.7 million while Tri-Shield First Defense sales grew 38.5% to $7.9 million; international sales fell 30.2%.
The company cited seasonal demand, inventory and manufacturing actions, and ongoing backorder effects. A conference call is scheduled for May 15, 2026 at 9:00 AM ET.
ImmuCell (Nasdaq: ICCC) appointed Kathy Turner to its Board of Directors effective April 1, 2026, replacing retiring director Steven Rosgen. Turner will chair the Compensation and Stock Option Committee and join the Audit Committee.
She brings 30+ years of global commercial leadership across animal health and healthcare, including prior board service at Elanco and senior roles at IDEXX and Abbott, and will support expansion of the First Defense® product internationally.
ImmuCell (Nasdaq: ICCC) reported unaudited results for the year ended December 31, 2025 showing product sales of $27.6M, up 4.3% year-over-year, and a gross profit margin of 41.4% versus 30.0% in 2024. Net loss narrowed to $1.0M, or ($0.12) per share.
Management cited higher volumes, manufacturing efficiencies and price realization; cash was $3.8M, inventory rose to $9.267M, and net working capital was $12.967M as of December 31, 2025.
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter and year ended December 31, 2025 after market close on March 4, 2026. The company will host a conference call on March 5, 2026 at 9:00 AM ET to review results.
Dial-in numbers, replay access (code #2017737) available through March 12, 2026. ImmuCell expects no change to preliminary sales disclosed January 8, 2026 and plans to file its Form 10-K on or before March 31, 2026.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q4 and full-year 2025. Q4 product sales were $7.6 million (down 1.6% year-over-year) with domestic $7.0M (+8.7%), international $0.62M (-52.6%), Tri-Shield $6.0M (+41.3%) and Dual-Force/other $1.7M (-53.0%). FY 2025 sales were $27.6M (+4.3%) with Tri-Shield $19.9M (+26.5%) and Dual-Force $7.7M (-28.2%).
The company received an FDA Incomplete Letter for Re-Tain (Dec 23, 2025), paused further Re-Tain investment and expects an approx. $2.9M non-cash impairment for Re-Tain assets and total Q4 write-downs of $3.6M. Management plans to repurpose most Re-Tain assets for First Defense and expand the sales force by 50%.
ImmuCell (Nasdaq: ICCC) will hold an investor conference call on Friday, January 9, 2026 at 9:00 AM ET to discuss its strategic shift in focus to the First Defense product line and away from Re-Tain, plus unaudited topline sales for the quarter and year ended December 31, 2025. The company will release those topline sales after market close on Thursday, January 8, 2026.
ImmuCell also plans to release full unaudited financial results for the quarter and year on Wednesday, February 25, 2026 with a follow-up call on Thursday, February 26, 2026 at 9:00 AM ET. Dial-in numbers and replay access codes are provided for both calls.
ImmuCell (Nasdaq: ICCC) received an FDA Incomplete Letter for its Re-Tain NADA on December 23, 2025 after four of five technical sections were deemed complete and the contract manufacturer failed to satisfactorily address inspectional deficiencies. ImmuCell will pause further investment in Re-Tain, complete ongoing investigational studies, and pursue licensing or partnering options that avoid further capital or in-house manufacturing expenditure.
ImmuCell is simultaneously increasing First Defense field sales by 50%, expanding First Defense manufacturing, and expects a ~$2.3 million estimated non-cash impairment in Q4 2025 (Re-Tain net book value was $15.5M as of Sept 30, 2025). First Defense reported $27.8M TTM revenue and holds a 29% U.S. spend share in scour prevention; company estimates a $900M worldwide TAM for scours prevention.
ImmuCell (Nasdaq: ICCC) reported unaudited results for the quarter ended September 30, 2025. Q3 product sales fell 8% to $5.5M, while nine-month product sales rose 7% to $20.0M and twelve-month sales rose 16% to $27.8M. The company posted net income of $1.8M for the nine months versus a loss of $2.7M year-ago, driven by higher sales and margin recovery.
Gross margin improved to 42.6% for the nine months (vs. 27.3% prior year). Adjusted EBITDA was $751k for Q3 and $4.42M for nine months. Balance sheet highlights: cash $3.9M, net working capital $12.8M, stockholders' equity $29.8M. Re-Tain remains in investigational use with Michigan State University while management addresses prior backlog.
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter ended September 30, 2025 after market close on Thursday, November 13, 2025. The company plans a conference call to review results on Friday, November 14, 2025 at 9:00 AM ET, accessible by dialing (844) 855-9502 (U.S.) or (412) 317-5499 (international). A teleconference replay will be available through November 21, 2025 using access code 7664668.
The company anticipates no change to preliminary third-quarter sales disclosed on October 7, 2025 and expects to file its Form 10-Q after market close on November 13, 2025. An updated corporate presentation will be posted under the Investors tab at www.immucell.com after the market close on November 13, 2025.
ImmuCell (Nasdaq: ICCC) announced leadership changes effective November 1, 2025: Olivier te Boekhorst began serving as President and CEO, succeeding Michael F. Brigham. At its October 29, 2025 meeting the board also appointed Timothy C. Fiori, who joined as CFO in April 2025, to the Board; Fiori will serve as CFO, Treasurer and Secretary.
Mr. Brigham will remain a board member and act as Special Advisor to the CEO through January 2026. The company plans a conference call on November 14, 2025 at 9:00 AM ET to discuss unaudited Q3 results and expects an updated corporate slide deck after market close on November 13, 2025.